Pharmafile Logo
Pharmafocus logo
Advanced Search

Cometriq

Showing 3 posts of 3 posts found.

NICE recommends thyroid cancer drug trio for NHS use

February 20, 2018
Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer

NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …

News

NICE provisionally rejects Ipsen’s kidney cancer drug Cabometyx

February 21, 2017
Manufacturing and Production, Sales and Marketing Cometriq, NICE, ipsen

NICE has announced draft guidance for Ipsen’s cancer drug Cabometyx (cabozantinib), revealing it does not recommend the drug for use on …

News
ipsen_logo

Exelixis signs $200 million licensing deal for cancer drug

March 1, 2016
Research and Development, Sales and Marketing Cancer, Cometriq, Exelixis, ipsen

Exelixis has signed a licensing agreement with French biotech firm Ipsen for its cancer drug Cometriq (cabozantinib) for an upfront …

News
The Gateway to Local Adoption Series

Latest content

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026